These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 9739502)

  • 21. alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects.
    Toeller M
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():31-5. PubMed ID: 8001625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].
    Kuboyama N; Hayashi I; Yamaguchi T
    Nihon Yakurigaku Zasshi; 2006 Mar; 127(3):223-32. PubMed ID: 16651808
    [No Abstract]   [Full Text] [Related]  

  • 23. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.
    Reuser AJ; Wisselaar HA
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():19-24. PubMed ID: 8001622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. alpha-Glucosidase inhibition in the treatment of diabetes mellitus.
    Dimitriadis G; Raptis S
    Horm Metab Res Suppl; 1992; 26():42-9. PubMed ID: 1490691
    [No Abstract]   [Full Text] [Related]  

  • 26. Miglitol and hepatotoxicity in type 2 diabetes mellitus.
    Carlson RF
    Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699
    [No Abstract]   [Full Text] [Related]  

  • 27. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
    Holman RR; Steemson J; Turner RC
    Diabetes Res; 1991 Dec; 18(4):149-53. PubMed ID: 1842749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The use of the alpha-glucosidase inhibitor acarbose for the treatment of type-2 diabetes mellitus in secondary sulfanilamide resistance].
    Gendeleka GF
    Lik Sprava; 1997; (6):105-7. PubMed ID: 9589946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?
    Joubert PH; Venter HL; Foukaridis GN
    Br J Clin Pharmacol; 1990 Sep; 30(3):391-6. PubMed ID: 2223417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
    Campbell LK; Baker DE; Campbell RK
    Ann Pharmacother; 2000 Nov; 34(11):1291-301. PubMed ID: 11098345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Inhibitors of alpha-glucosidase].
    Toeller M
    Journ Annu Diabetol Hotel Dieu; 1991; ():203-12. PubMed ID: 1886331
    [No Abstract]   [Full Text] [Related]  

  • 33. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
    Santeusanio F; Compagnucci P
    Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
    Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
    Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
    Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM
    Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology of alpha-glucosidase inhibition.
    Bischoff H
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():3-10. PubMed ID: 8001624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evolving role of alpha-glucosidase inhibitors.
    Göke B; Herrmann-Rinke C
    Diabetes Metab Rev; 1998 Sep; 14 Suppl 1():S31-8. PubMed ID: 9816485
    [No Abstract]   [Full Text] [Related]  

  • 39. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical experience with acarbose as first line therapy in NIDDM.
    Fölsch UR
    Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.